Verve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of Buy by Analysts

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) has earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among […]

Related Keywords

California ,United States ,Canada ,Hong Kong ,Burta Adelman ,Stifel Nicolaus ,Goldman Sachs Group Inc ,Zacks Investment Research ,Ensign Peak Advisors Inc ,Verve Therapeutics Inc ,Nasdaq ,Hong Kong Ltd ,Royal Bank ,Verve Therapeutics ,Get Rating ,Investment Research ,Director Burt ,Kong Ltd ,Peak Advisors Inc ,State Teachers Retirement System ,Sachs Group ,State Street Corp ,Street Corp ,Nasdaq Verv ,Everv ,Medical ,Ratings ,Consensus ,